OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC
Martin Reck, Ernest Nadal, Nicolas Girard, et al.
Clinical Lung Cancer (2024) Vol. 25, Iss. 6, pp. 587-593.e3
Closed Access | Times Cited: 12
Martin Reck, Ernest Nadal, Nicolas Girard, et al.
Clinical Lung Cancer (2024) Vol. 25, Iss. 6, pp. 587-593.e3
Closed Access | Times Cited: 12
Showing 12 citing articles:
Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
Identification of cancer cell-intrinsic biomarkers associated with tumor progression and characterization of SFTA3 as a tumor suppressor in lung adenocarcinomas
Yu Zhao, Chengcheng Zhou, Ling Zuo, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Yu Zhao, Chengcheng Zhou, Ling Zuo, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Immunotherapy for early-stage non-small cell lung cancer: A practical guide of current controversies
William J. Phillips, Ashley Jackson, Biniam Kidane, et al.
Clinical Lung Cancer (2025)
Open Access
William J. Phillips, Ashley Jackson, Biniam Kidane, et al.
Clinical Lung Cancer (2025)
Open Access
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial
Liang Zeng, Huan Yan, Wenjuan Jiang, et al.
Med (2025), pp. 100574-100574
Closed Access
Liang Zeng, Huan Yan, Wenjuan Jiang, et al.
Med (2025), pp. 100574-100574
Closed Access
Bibliometric insight into neoadjuvant immunotherapy in non-small cell lung cancer: trends, collaborations, and future avenues
Pengliang Xu, Huanming Yu, Hongqiang Bian, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Pengliang Xu, Huanming Yu, Hongqiang Bian, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows”
Marco Donatello Delcuratolo, Veronica Crespi, Giorgio Saba, et al.
Cancer Treatment Reviews (2025) Vol. 135, pp. 102918-102918
Open Access
Marco Donatello Delcuratolo, Veronica Crespi, Giorgio Saba, et al.
Cancer Treatment Reviews (2025) Vol. 135, pp. 102918-102918
Open Access
The Short-Term Impact of Neoadjuvant Chemotherapy on the Outcome of Patients Undergoing Pneumonectomy for Lung Cancer: Is It Acceptable Nowadays?
Antonio Mazzella, Sebastiano Maiorca, G NICOLOSI, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 7, pp. 2419-2419
Open Access
Antonio Mazzella, Sebastiano Maiorca, G NICOLOSI, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 7, pp. 2419-2419
Open Access
The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis
Lye-Yeng Wong, Douglas Z. Liou, Mohana Roy, et al.
JTO Clinical and Research Reports (2024) Vol. 5, Iss. 3, pp. 100654-100654
Open Access | Times Cited: 1
Lye-Yeng Wong, Douglas Z. Liou, Mohana Roy, et al.
JTO Clinical and Research Reports (2024) Vol. 5, Iss. 3, pp. 100654-100654
Open Access | Times Cited: 1
Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis
Leyla Ay, Daniel Steiner, Hannah Fabikan, et al.
Lung Cancer (2024) Vol. 198, pp. 107997-107997
Open Access
Leyla Ay, Daniel Steiner, Hannah Fabikan, et al.
Lung Cancer (2024) Vol. 198, pp. 107997-107997
Open Access
Determining optimal clinical target volume margins based on microscopic extracapsular extension of metastatic nodes in patients with non-small-cell lung cancer after chemotherapy or chemotherapy combined with immunotherapy
Yujiao Zhang, Jiaran Li, Xiao Song, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
Yujiao Zhang, Jiaran Li, Xiao Song, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer
M. Mayenga, Ana Rita Pedroso, Marion Ferreira, et al.
Breathe (2024) Vol. 20, Iss. 3, pp. 240044-240044
Open Access
M. Mayenga, Ana Rita Pedroso, Marion Ferreira, et al.
Breathe (2024) Vol. 20, Iss. 3, pp. 240044-240044
Open Access
Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights
Navneet Singh, Martin Früh, Matthew A. Gubens, et al.
JCO Oncology Practice (2024)
Closed Access
Navneet Singh, Martin Früh, Matthew A. Gubens, et al.
JCO Oncology Practice (2024)
Closed Access
